New drug strategy reverses resistance to immunotherapy in pancreatic cancer

A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a susceptible one, according to a study by researchers from the Johns Hopkins Kimmel Cancer Center and Oregon Health & Science University.

New insights on 5-fluorouracil’s mechanism in different cancers

Study reveals the drug, 5-fluorouracil, acts differently in different types of cancer — a finding that could help researchers design better drug combinations.

October 7, 2024

Valo Health appoints Brian Alexander as CEO

Alexander has two decades of experience in biotechnology. Credit: Flagship Pioneering/PR Newswire. Flagship Pioneering-founded Valo Health has announced the appointment of Dr Brian Alexander as

November 14, 2024

Roivant says long-shot drug for a rare lung disease failed its Phase 2 study

Roivant reported a Phase 2 failure on Tuesday for a program analysts expected would not succeed. The compound in question, namilumab, was being tested in

December 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.